Pharmaceuticals, Biotechnology and Life Sciences
Sanofi and Regeneron will continue marketing, selling and manufacturing Praluent in the United States (U.S.) during their appeal on Amgen’s patent claims.
Bayer’s and Janssen R&D’s drug for cardiac situations has already met its primary goals in the early third phase of testing, the companies said today, which concludes the testing.
U.S. Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research (CDER) does not plan to hold an Advisory Committee meeting with Portola Pharmaceuticals for New Drug Application (NDA) for betrixaban, Portola said on Wednesday.
GlaxoSmithCline has posted net profit in the fourth quarter 2016 of £1,062 million and fully year £8,372, and turnover revenue growth of 6% with sales mounting to £27.9 billion, mainly driven by continued strong performance of new products.
Allergan’s net revenue for the fourth quarter 2016 rose 7 percent to $3.86 billion, mostly driven by better sales of Botox, Linzess and certain other new products.
Eli Lilly has updated its Trulicity label to now include use in combination with basal insulin for adults with type 2 diabetes.
Amgen has been given green light in the USA for its Parsabiv, the cure for chronic kidney disease patients on hemodialysis to treat secondary hyperparathyroidism (HPT).
Two remaining late-stage clinical trials testing an experimental Alzheimer’s drug from Denmark’s Lundbeck have failed, scuppering hopes for the medicine and underscoring the difficulty of developing such treatments.
French biotechnology company Lysogene has kicked off well with its initial public offering on Euronext Paris stock market by raising €22.6 million.
US Government Services Administration (GSA) has awarded MDxHealth to supply Department of Veterans Affairs (VA) with ConfirmMDx for Prostate Cancer.